Friday 6 November 2026 Export BIO’s income statement to Excel — free account

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.

Revenue: +0.52%
EPS: +234.9%
Free cash flow: +8.07%
Total debt: +0.11%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

381.91 12.91 +3.50%

Follow BIO

Alert me

Market cap: $9.9B
P/E: 9.7×
Fwd P/E: 44.7×
Dividend yield: —
F-score: 5/9
Altman Z: 3.20
Beneish M: −2.29
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Bio-Rad Laboratories, Inc. (BIO) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Bio-Rad Laboratories, Inc. (BIO) trades at a EV/FCF of 28.8×. Over the past ten years it has ranged from −13,178× (August 2017) to 542× (June 2017); the current reading is higher than 25% of that period.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/BIO/ev-fcf" width="100%" height="360" style="border:0" loading="lazy" title="Bio-Rad Laboratories, Inc. EV/FCF, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/BIO/metrics/ev-fcf">Bio-Rad Laboratories, Inc. (BIO) EV/FCF — stockrow.com</a></p>

Period	EV/FCF	Change
FY2025	21.0×	(30.33%)
FY2024	30.2×	(27.42%)
FY2023	41.6×	(70.91%)
FY2022	143×	255.69%
FY2021	40.2×	17.84%
FY2020	34.1×	21.25%
FY2019	28.1×	(30.94%)
FY2018	40.7×	—
FY2017	−619×	—
FY2016	66.5×	31.35%

Period	EV/FCF	Change
Sep 2026	29.3×	40.08%
Jun 2026	20.9×	5.24%
Mar 2026	19.9×	(5.37%)
Dec 2025	21.0×	(2.80%)
43 more quarters	Free account

Against its own ten years

Low −13,178× High 542×

Ten-year median 38.1×

Current reading's percentile 19

Company	EV/FCF
SNN Smith & Nephew SNATS, Inc. compare	8.3×
GMED Globus Medical, Inc. compare	14.9×
BIO Bio-Rad Laboratories, Inc.	28.8×
BIO.B Bio-Rad Laboratories, Inc. compare	29.5×
BRKR Bruker Corporation compare	38.8×
PODD Insulet Corporation compare	48.0×
TXG 10x Genomics compare	58.9×
PEN Penumbra, Inc. compare	59.8×
GKOS Glaukos Corporation compare	360×

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

Bio-Rad Laboratories, Inc. (BIO) EV/FCF

EV/FCF, daily

Annual newest first

Quarterly newest first

Against its own ten years

EV/FCF against peers

What EV/FCF is

More on BIO

EV/FCF, daily

Annual newest first

Quarterly newest first

Against its own ten years

EV/FCF against peers

What EV/FCF is

More on BIO

Stockrow Weekly